MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.70176

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2025

Health-Related Quality of Life in Egyptian Children With Haemophilia A and Chronic Arthropathy With the Era of Emicizumab Therapy: A Single-Centre Cohort Study.

Khalifa Gehan Lotfy Abdel Hakeem, Tawab Rawhya Rabei Abdel, Bahaa Mohamed Ahmed, Lotfi Alaa Mukhtar, Laklouk Mouhamed Abdel Rahim, Wali Yasser, Samei Ebtihal Mokhtar Abdel

СтатьяПеревод в очереди

Аннотация

AIM: To assess the health-related quality of life (HRQOL) in children with haemophilia A and arthropathy before and after emicizumab prophylaxis using the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool questionnaire Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) v3.0 and haemophilia family impact tools (H-FIT).

METHODS

Eighty-four children with haemophilia A and chronic arthropathy, recruited at Minia University HTC, and their parents/caregivers completed CHO-KLAT and H-FIT questionnaires before and after starting emicizumab. All patients underwent clinical and radiological joint assessments (HJHS, HEAD-US, CHAQ). Only 44 of them were confirmed to have chronic haemophilic arthropathy.

RESULTS

After emicizumab prophylaxis, pain scores decreased significantly (p = 0.0001), while H-FIT scores and CHO-KLAT domain scores (physical activities, bleeding, knowledge, social functioning, treatment, autonomy, environment) increased significantly (p ≤ 0.002 for autonomy/environment; p = 0.0001 for others and total CHO-KLAT). Comparing arthropathic (n = 44) and non-arthropathic (n = 40) patients after initiation of emicizumab, the arthropathic group had significantly higher pain scores and lower H-FIT scores (p = 0.001) but similar total CHO-KLAT scores (p = 0.63). Following emicizumab initiation and implementation of a planned physiotherapy program in the arthropathic group, significant reductions occurred in pain scores, HJHS, HEAD-US, and CHAQ scores (p = 0.0001 for all). No significant correlation existed between the total CHO-KLAT score and HJHS or HEAD-US scores before or after emicizumab administration.

CONCLUSION

Emicizumab prophylaxis significantly improved HRQoL and reduced joint pain in children with haemophilia A and chronic arthropathy. When combined with a planned physiotherapy program, it further leads to significant improvements in objective joint health outcomes.

Для цитирования: Khalifa Gehan Lotfy Abdel Hakeem, Tawab Rawhya Rabei Abdel, Bahaa Mohamed Ahmed, Lotfi Alaa Mukhtar, Laklouk Mouhamed Abdel Rahim, Wali Yasser, Samei Ebtihal Mokhtar Abdel. Health-Related Quality of Life in Egyptian Children With Haemophilia A and Chronic Arthropathy With the Era of Emicizumab Therapy: A Single-Centre Cohort Study.. Haemophilia : the official journal of the World Federation of Hemophilia. 2025. DOI: 10.1111/hae.70176.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.